Atlas Trials

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Clinical trial NCT05411757 · UNKNOWN

Trial details

NCT number
NCT05411757
Sponsor
Shandong Public Health Clinical Center
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
Advanced Primary Liver Cancer
Start date
2022-06-30
Primary completion
2023-06-30
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.